Clinical concerns of alendronate use

Journal of Oral and Maxillofacial Surgery

Volumn 65, Issue 2, 2007, Pages 363-364

  Rutkowski, James L ^a   Johnson, David A ^a   Smith, Douglas M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; ANGIOGENESIS; APOPTOSIS; BONE DENSITY; BONE NECROSIS; BONE TURNOVER; CELL PROLIFERATION; DENTAL SURGERY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LETTER; LONG TERM CARE; MOUTH INJURY; ORAL OSTEOCHEMONECROSIS; ORAL SURGERY; OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; PAGET BONE DISEASE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JAW DISEASES; ORAL SURGICAL PROCEDURES; OSTEONECROSIS;

EID: 33846201186     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2006.02.025     Document Type: Letter

References (10)

1. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
2. Giuliani N., Pedrazzoni M., Negri G., et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22 (1998) 455
3. Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286 (1999) 1946
4. Giuliani N., Girasole G., Pedrazzone M., et al. Alendronate stimulates β-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10 1 (1995) S171
5. Im G.I., Qureshi S.A., Kenney J., et al. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25 (2004) 4105
6. Azuma Y., Sato H., Que Y., et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 17 (1995) 333
7. Green J., and Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25 1 (2002) S3
8. Carter G., Goss A.N., and Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 182 (2005) 413
9. Bjarnason N.H. Ten years of alendronate treatment for osteoporosis in postmenopausal women. [Correspondence] NEJM 351 (2004) 190
10. Ravn P., Bidstrup M., Wasnich R.D., et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. Ann Intern Med 131 (1999) 935